APA

van de Putte L. B. A., Rau R., Breedveld F. C., Kalden J. R., Malaise M. G., van Riel P. L. C. M., Schattenkirchner M., Emery P., Burmester G. R., Zeidler H., Moutsopoulos H. M., Beck K. & Kupper H. (20040126). Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. : Annals of the rheumatic diseases.

Chicago

van de Putte L B A, Rau R, Breedveld F C, Kalden J R, Malaise M G, van Riel P L C M, Schattenkirchner M, Emery P, Burmester G R, Zeidler H, Moutsopoulos H M, Beck K and Kupper H. 20040126. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. : Annals of the rheumatic diseases.

Harvard

van de Putte L. B. A., Rau R., Breedveld F. C., Kalden J. R., Malaise M. G., van Riel P. L. C. M., Schattenkirchner M., Emery P., Burmester G. R., Zeidler H., Moutsopoulos H. M., Beck K. and Kupper H. (20040126). Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. : Annals of the rheumatic diseases.

MLA

van de Putte L B A, Rau R, Breedveld F C, Kalden J R, Malaise M G, van Riel P L C M, Schattenkirchner M, Emery P, Burmester G R, Zeidler H, Moutsopoulos H M, Beck K and Kupper H. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. : Annals of the rheumatic diseases. 20040126.